Well-designed clinical trials with depression as a primary outcome measure are needed to establish whether GLP-1 agonists have genuine antidepressant properties independent of their metabolic effects
As more people become aware of these medications and the stigma associated with seeking treatment for obesity ebbs, this demand will continue to rise: Research from the University of Southern California showed a 442% increase in prescriptions for semaglutide between January 2021 and December 2023
In another phase 2 trial of obese patients with type 2 diabetes, the combination of cagrilintide 2.4 mg/week and the GLP-1R semaglutide 2.4 mg/week (referred to as CagriSema) was compared with each drug alone
KNOW THIS: Theyre not all FDA approved
BOTTOM LINE There is still much more for us to learn about L-carnitine, but if you are serious about taking it, make sure you are making this a long-term change, as in the short term its likely you wont see much change
Concerning BPC-157, a natural pentadecapeptide that acts as a cytoprotectant